BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15102596)

  • 1. Application of IL-2 and other cytokines in renal cancer.
    McDermott DF; Atkins MB
    Expert Opin Biol Ther; 2004 Apr; 4(4):455-68. PubMed ID: 15102596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
    McDermott DF; Atkins MB
    Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
    McDermott DF
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines.
    Dutcher J; Atkins MB; Margolin K; Weiss G; Clark J; Sosman J; Logan T; Aronson F; Mier J;
    Med Oncol; 2001; 18(3):209-19. PubMed ID: 11917945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials.
    Atkins MB; Dutcher J; Weiss G; Margolin K; Clark J; Sosman J; Logan T; Aronson F; Mier J;
    Med Oncol; 2001; 18(3):197-207. PubMed ID: 11917944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
    Atkins MB; Regan M; McDermott D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytokine therapy for metastatic renal cell carcinoma].
    Eto M; Naito S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
    Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
    Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M
    J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2: clinical applications.
    Atkins MB
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):12-7. PubMed ID: 12068383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature.
    Malaguarnera M; Ferlito L; Gulizia G; Di Fazio I; Pistone G
    Eur J Clin Pharmacol; 2001 Jul; 57(4):267-73. PubMed ID: 11549203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.
    Atzpodien J; Kirchner H; Hänninen EL; Deckert M; Fenner M; Poliwoda H
    Eur J Cancer; 1993; 29A Suppl 5():S6-8. PubMed ID: 8260264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for renal cell carcinoma.
    Rosenblatt J; McDermott DF
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting survival of patients with metastatic renal cell carcinoma.
    Motzer RJ; Mazumdar M
    Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
    Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.